Document is current
Any future updates will be listed below
-
Authors
McAllister, Mark
Ko, Stella
Bawa, Komal
Mearns, Elizabeth
Tabano, David https://orcid.org/0000-0001-7657-0809
Martinez, Amanda https://orcid.org/0009-0009-3476-7019
Faux, Nancy
Patel, Shriji
Spicer, Galin https://orcid.org/0009-0000-4423-582X
Lim, Jennifer I.
-
Funding
Funding for this research was provided by:
Genentech
- License Information
-
More Information
Article History
Received: 18 November 2024
Revised: 5 September 2025
Accepted: 19 September 2025
First Online: 1 October 2025
Competing interests
: The authors made the following disclosures: SK: Employee – Genentech, Inc.; DT: Employee – Genentech, Inc.; KB: Employee – Genentech, Inc. (At time of study); EM: Employee – Genentech, Inc.; SP: Employee – Genentech, Inc.; GS: Employee – Genentech, Inc.; JIM: Consultant/Advisor – AbbVie/Allergan, Alimera, Astellas/Iveric Bio, Aura, Cognition, EyePoint, Eyenuk, Genentech/Roche, Luxa, Novartis, Regeneron, Unity, Viridian; Grant Support – Aldeyra, Adverum, BioSpring Vision, Genentech, Inc., Graybug, Janssen, Kyoto Drug Development, NGM Bio, Regeneron, Regenex, Stealth; Honoraria – Bausch + Lomb, Iveric Bio. The other authors have no proprietary or commercial interest in any materials discussed in this article.
